Results 41 to 50 of about 1,026 (172)

Bulevirtide\u6cbb\u7597\u6162\u6027\u4e01\u578b\u809d\u708e\u7814\u7a76\u73b0\u72b6\u548c\u9762\u4e34\u7684\u6311\u6218

, 2022
In July of 2020, bulevirtide was conditionally approved for the treatment of adults with compensated chronic hepatitis D. Some clinical studies have evaluated the safety and efficacy of bulevirtide as a treatment option for chronic hepatitis D in recent ...

core   +1 more source

Real‐life experiences with bulevirtide for the treatment of hepatitis delta—48 weeks data from a German centre [PDF]

, 2022
In July 2020, the entry inhibitor bulevirtide was approved in the European Union for the treatment of chronic hepatitis delta virus (HDV) infection. We describe the first 48 weeks of bulevirtide therapy in eight patients (n = 7 male, n = 1 female; n = 3 ...
Demir, Münevver, Lutz, Katrin, Hofmann, Jörg, Tacke, Frank, Zöllner, Caroline   +4 more
core   +1 more source

Characterising Hepatitis D Virus in the UK From 2011 to 2021. [PDF]

J Viral Hepat
ABSTRACT Little is known about hepatitis B virus (HBV) and Hepatitis D virus (HDV) coinfection in the UK. HDV screening is recommended among all individuals with HBV, with coinfection associated with increased disease progression. Using data on HDV testing, shared by 11 laboratories in the UK who reported undertaking HDV testing, and national testing ...
Simmons R, Ijaz S, Jackson R, Jack K, Mulongeni R, Raghu R, Riddell A, Elsharkawy A, Uriel A, Koffas A, Chaika A, Lawson A, Cole A, McEwan A, Brown A, Stone B, Levick C, Byrne D, Forton D, MacDonald D, Forde D, Nastouli E, Barnes E, Sumner E, Page E, Carey I, Vilar FJ, Maggs J, Collier J, Shepherd J, Agarwal K, Bicknell K, Ala K, Dear K, Ratcliffe L, Bruce M, Zhang H, Rivett L, Maes M, Ankcorn M, Aldersley M, Prince M, Lemoine M, Foxton M, Wright M, Cramp M, Wiselka M, Easom N, Richardson P, Gunson R, Herbert R, Blackwell R, Jelley R, Aspinall R, Simpson R, Clewes R, Ahmad S, Mcpherson S, Ryder S, Verma S, Lampejo T, Sathyanarayana V, Gelson W, Leeman D, Desai M, Mandal S, Kennedy PT, Irving WL.   +67 more
europepmc   +2 more sources

Real life study of bulevirtide in chronic hepatitis delta: preliminary results of the ANRS HD EP01 BuleDelta prospective cohort

, 2022
International audienceReal life study of bulevirtide in chronic hepatitis delta: preliminary results of the ANRS HD EP01 BuleDelta prospective ...
de Ledinghen, Victor, Tual, Christelle, Roulot, Dominique, Leroy, Vincent, Zoulim, Fabien, Ratziu, Vlad, Ganne-Carrié, Nathalie, Fontaine, Hélène, Dumortier, Jérôme, Gordien, Emmanuel, Guyader, Dominique, Pageaux, Georges-Philippe, Marchand, Lucie, Scholtès, Caroline, Alric, Laurent, Métivier, Sophie, Renault, Alain, Loustaud-Ratti, Véronique, Lacombe, Karine, Le Pabic, Estelle, Fougerou-Leurent, Claire, Franza, Anne Minello   +21 more
core   +1 more source

“Real world” efficacy of bulevirtide in HBV/HDV-related cirrhosis including people living with HIV: Results from the compassionate use programme at INMI Spallanzani in Rome, Italy [PDF]

, 2023
Objectives: We describe the preliminary results of bulevirtide compassionate use in patients with hepatitis B and delta virus (HBV/HDV)-related cirrhosis and clinically significant portal hypertension, including those living with HIV.
Maggi F., Taibi C., Rianda A., Mazzotta S., De Maria F., D'Offizi G., Visco Comandini U., Lionetti R., De Ponte C., Piccolo P., Caioli A., De Santis E., Montalbano M., Garbuglia A. R.   +13 more
core   +1 more source

Multiple Regions Drive Hepatitis Delta Virus Proliferation and Are Therapeutic Targets

Frontiers in Microbiology, 2022
Hepatitis Delta Virus (HDV) is the smallest mammalian single-stranded RNA virus. It requires host cells and hepatitis B virus (HBV) to complete its unique life cycle.
Jun Zi, Xiuzhu Gao, Juan Du, Hongqin Xu, Junqi Niu, Xiumei Chi   +5 more
doaj   +1 more source

Autoimmune Hepatitis Induced by Hepatitis Delta Virus: A Conundrum

GE: Portuguese Journal of Gastroenterology, 2023
Introduction: The association of hepatitis delta virus (HDV) infection with positive autoantibodies and autoimmune features has been known for decades.
Mariana F. Cardoso, Rita Carvalho, Fábio Pereira Correia, Joana C. Branco, Mariana Nuno Costa, Alexandra Martins   +5 more
doaj   +1 more source

Hepatitis D virus infection in persons with HIV and hepatitis B virus across Europe: A cross‐sectional analysis of the HDV‐Europe cohort

HIV Medicine, EarlyView.
Abstract Introduction Infection with hepatitis D virus (HDV) is known to accelerate the progression of liver disease and is associated with mortality in individuals with HIV and hepatitis B virus (HBV). However, little is known about current HDV epidemiology, including HDV‐testing practices and prevalence, in this population in Europe.
Anders Boyd, Thomas Lutz, Kathrin van Bremen, Alessandro Tavelli, Antonella d'Arminio Monforte, Marc van der Valk, Miłosz Parczewski, Magdalena Tchorz, Iwona Cielniak, Luz Martín‐Carbonero, María del Mar Arcos‐Rueda, Charles Béguelin, Gilles Wandeler, Sanjay Bhagani, Charlotte Lim, Fauzi Elamouri, Juan Berenguer, Jürgen K. Rockstroh, Pablo Ryan   +18 more
wiley   +1 more source

Metabolic Effect of Blocking Sodium-Taurocholate Co-Transporting Polypeptide in Hypercholesterolemic Humans with a Twelve-Week Course of Bulevirtide—An Exploratory Phase I Clinical Trial

, 2022
Bile acids (BA) play an important role in cholesterol metabolism and possess further beneficial metabolic effects as signalling molecules. Blocking the hepatocellular uptake of BA via sodium-taurocholate co-transporting polypeptide (NTCP) with the first ...
Walter E. Haefeli, Burghaus, Ina, Felicitas Stoll, Riffel, Johannes, Blank, Antje, Göring, Oliver, Oliver Göring, Schwab, Matthias, Lenka Taylor, Ina Burghaus, Johannes Riffel, Rose, Peter, Andrea Seidel-Glätzer, Max Sauter, Peter Rose, André, Florian, Volker Daniel, Johanna Weiss, Cleeves, Volker, Haefeli, Walter E., Matthias Schwab, Mathias Haag, Seidel-Glätzer, Andrea, Taylor, Lenka, Daniel, Volker, Florian André, Burhenne, Jürgen, Stoll, Felicitas, Sauter, Max, Antje Blank, Jürgen Burhenne, Weiss, Johanna, Volker Cleeves, Haag, Mathias   +33 more
core   +1 more source

Hepatitis B in Organ Transplantation—Current Evidence and Clinical Gaps

Transplant Infectious Disease, EarlyView.
ABSTRACT Over the past several decades there have been significant advances in nucleos(t)ide analogue (NA) antiviral therapy for hepatitis B virus (HBV) and global expansion of primary prevention through immunization. Despite this, HBV remains a leading cause of chronic liver disease globally, affecting over 250 million people.
Oscar A. Fernandez‐Garcia, Britta L. Hirsch, Irene A. Abela, Karen E. Doucette   +3 more
wiley   +1 more source